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ABSTRACT
Introduction: Acute myocardial infarction (AMI)
remains a major cause of mortality and morbidity
worldwide despite the latest therapeutic advances
designed to decrease myocardial injury. Preclinical and
emerging clinical evidence show that the intracoronary
injection of autologous bone marrow mononuclear
cells (BMCs) following AMI leads to improvement in
left ventricular ejection function (LVEF). In this clinical
trial we will for the first time assess the effect of early
(<24 h) infusion of autologous BMCs following AMI on
cardiac function.
Methods and analysis: REGENERATE-AMI is a
double-blind, randomised, multicentre, placebo-
controlled trial to determine whether early (<24 h)
intracoronary infusion of BMCs improves LVEF after AMI.
The study will enrol 100 patients presenting with an
anterior AMI demonstrating anterior regional wall motion
abnormality. Patients will be randomised to receive
intracoronary infusion of BMCs or placebo (0.9% saline).
Primary endpoint will be change in LVEF at 1 year
compared to baseline, measured by cardiac MRI.
Secondary endpoints at 6 months include the change in
global LVEF relative to baseline measured by quantitative
left ventriculography and echocardiography, as well as
major adverse cardiac events which is also measured at
1 year.
Ethics and dissemination: The study will be
performed in agreement with the Declaration of Helsinki
and is approved by local ethics committee (NRES
Committee London West London: 07/Q0603/76).
Trial registration: http://clincialtrials.gov
(NCT00765453). The results of the trial will be published
according to the CONSORT statement and will be
presented at conferences and reported in peer-reviewed
journals.
INTRODUCTION
Cardiovascular disease (CVD) remains the
most common cause of death in the world,
accounting for an estimated 17.3 million
deaths in 2008, representing 30% of all
deaths worldwide.1 In the UK CVD accounts
for almost 191 000 deaths each year, almost
half (46%) of which is from ischaemic heart
disease (IHD). IHD is the most common
cause of death in the UK (mainly as a conse-
quence of acute myocardial infarction
(AMI)), causing approximately 82 000 deaths
per year, and accounting for £29.1 billion
pounds1 within the National Health Service
(NHS).1
Primary angioplasty has significantly
improved the outcome for patients with AMI,
however there remains a significant risk of mor-
tality at 30 days (7%) despite optimal medical
management.2 As treatment improves, there is
an increase in the numbers of survivors of AMI
but this means that there is also an associated
increase in the incidence of heart failure (15–
20%) in patients who still develop significant
myocardial damage.3 While early reperfusion
therapy directly decreases the amount of myo-
cardial necrosis, a consequence of ischaemic
damage, at least 50% of the final infarct size
results from the damage caused by
ischaemia-reperfusion (I-R) injury.4 5 This
means that there are two targets for thera-
peutic intervention in the early stages of AMI;
decreasing initial myocardial ischaemia by
Strengths and limitations of this study
▪ This is the first randomised control trial testing
early infusion of bone marrow mononuclear cells
to improve left ventricular ejection function.
▪ REGENERATE-AMI is a multicenter clinical trial
of cell therapy.
▪ Each centre will use local cell processing facil-
ities following a standardised protocol.
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prompt restoration of coronary flow and preventing the
damage caused by I-R injury as the blood supply is restored.
While early reperfusion is achieved by primary percutan-
eous coronary intervention (PPCI) it is possible that cell
therapy may play a role in limiting the I-R injury.6 This,
therefore, provides an additional rationale for administer-
ing cell therapy at an early stage after myocardial infarc-
tion, which is independent of the concept of cardiac
regeneration and has important therapeutic potential.
THE HEART AND REGENERATION
Until recently the heart has been considered as a ter-
minally differentiated organ with no ability to self repair
(cf hepatic regeneration).7 However, recent studies8–10
imply that there may be a background level of cellular
renewal by engraftment and differentiation of primitive
cells. Limited regeneration could occur through circulat-
ing primitive bone marrow mononuclear cells (BMCs)
that could engraft in the heart in response to injury11 or
from a resident cardiac stem cell population.12 Clearly,
this reparative potential is not capable of an adequate
response to significant myocardial damage but the dis-
covery of this endogenous repair process has provided a
further rationale for the use of cell therapy based on the
amplification of this natural process.
STEM CELL THERAPY AND MYOCARDIAL INFARCTION
The seminal work by Orlic et al13 in 2001 demonstrated
a significant increase in cardiac function following injec-
tion of allogeneic bone marrow-derived cells 3–5 h after
a mechanically induced myocardial infarction in a
mouse model. In further separate preclinical studies in
which progenitor cells were injected 1 h after induction
of myocardial infarction an angiogenesis-type response
was seen in the release of angiogenic ligands and related
cytokines compared to the controls.14–16 Recent experi-
ments using mouse models have shown that earlier infu-
sion time (immediate, compared to 1 week) and higher
cell concentration has a greater impact on left ventricu-
lar (LV) function post-mechanical infarction.17 These
studies, therefore, support the rationale of the trial
design reported here for attempting to deliver cell
therapy as soon as possible after AMI.
AMI STEM CELL THERAPY IN MAN
To date, the majority of clinical trials evaluating stem
cell therapy after AMI have been phase I or II studies
designed to look for safety and feasibility with surrogate
measures for early signs of efficacy. The first randomised
trial investigating cell use post-AMI was TOPCARE-AMI.
This showed an improvement in the LV function from
51.6±9.6% at baseline to 60.1±8.6% at 4 months in the
cell therapy arm vs 51.0±10% at baseline to 53.5±7.9% in
the control arm.18 Improvement in patients treated with
cell therapy was also seen in the BOOST study (bone
marrow transfer to enhance ST elevation infarction
regeneration) that demonstrated a 6.7% improvement
in LV function at 6 months from baseline in the stem
cell arm compared to 0.7% in the control arm
(p=0.0026).19 The largest randomised control trial to
date is the REPAIR-AMI trial (intracoronary progenitor
cells in AMI). This double-blinded, placebo-controlled
trial of 204 patients assessed LV function change after
4 months in patients treated with autologous bone
marrow-derived cell therapy compared to controls.
REPAIR-AMI showed a statistically significant improve-
ment in LV function in cell-treated patients compared to
the control arm (5.5±7.3%. vs 3.0±6.5%, p=0.01).20
Further follow-up of patients with REPAIR-AMI has
demonstrated a reduction in mortality in the cell-treated
group although the trial was not statistically powered to
assess this.
In contrast to these studies, a number of clinical trials
have been published that failed to reproduce these posi-
tive findings. In the LEUVEN-AMI, Janssens et al,
reported no change in global left ventricular ejection
function (LVEF) after autologous BMCs administration
24 h following myocardial infarction. Subgroup analysis
for this trial did however demonstrate a reduction in
infarct size in cell-treated patients compared to controls.
It is not clear why this improvement did not lead to
beneficial effects on LV function.21 In addition,
ASTAMI22 and HEBE23 trials have both failed to show
beneficial effect of BMCs on LVEF and LV volumes in
patients with AMI. Recently published trials have exam-
ined the effect of the timing of infusion of cell therapy
on outcome. The LATE TIME study, a double-blinded,
randomised, controlled trial of 87 patients showed no
improvement in LVEF after cell infusion therapy at
2–3 weeks post-AMI.24 The TIME trial (a randomised
controlled trial (RCT) of 120 patients) also failed to
show improvement in LVEF with a late infusion at 7 days
postinfarction. Interestingly, this trial also looked at infu-
sion at 3 days postinfarction but unlike REPAIR-AMI and
BOOST it failed to show statistically significant improve-
ment in LV function.25 In addition to this, the literature
has not reported any significant harm following early
injection of BMCs in animal models, despite the views of
some that this may be hazardous either to the subject or
the cell products. The aim of REGENERATE-AMI is to
ensure that this lack of evidence is addressed in the
safety analysis of the trial.
There has been considerable debate regarding the dis-
crepancies in the results of these clinical trials and also
the failure to translate the success of preclinical experi-
ments into man.13 Possible explanations include varia-
tions in the cell processing methods, the use of
adjunctive therapies and the patient population, high-
lighting the need for a standardised, widely applicable
approach in order to assess whether cell therapy has a
role in the management of myocardial infarction.
Bearing in mind these issues and the preclinical bene-
fits of early delivery of cell therapy, REGENERATE-AMI
has been designed to establish for the first time whether
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an early time point for delivery of cells (<24 h) is safe,
beneficial and feasible when used as an adjunct to the
established treatment of AMI. Patients presenting to
heart attack centres with evidence of large infarcts (anter-
ior territory) will have their bone marrow taken and then
be randomised to receive either the mononuclear frac-
tion from this sample or saline alone. This phase II clin-
ical trial is novel in the timing of the infusion of the bone
marrow-derived product (less than 24 h following index
revascularisation procedure). This time point will be the
closest to that used in the preclinical models, which
demonstrated a significant benefit in restoration of
cardiac function. Additionally, the inclusion of only anter-
ior AMIs will target the patient population most likely to
benefit as identified in the earlier trials.13–17 The cell
preparation technique will use the methodology of the
REPAIR-AMI trial.
METHODS AND ANALYSIS
Study design
REGENERATE-AMI is a double-blind, randomised, mul-
ticentre, placebo-controlled trial to determine whether
the intracoronary infusion of autologous bone marrow
progenitor cells is feasible, safe and shows positive evi-
dence of activity (ie, improves cardiac function) after an
acute anterior myocardial infarction (see figure 1) when
administered in addition to standard care.
Aims
1. To demonstrate that it is safe and feasible to deliver
autologous bone marrow-derived stem cells within
24 h of the primary angioplasty procedure (as
opposed to days as in previous studies).
2. To demonstrate that administration of autologous
bone marrow-derived stem cells (in addition to stand-
ard care) leads to improvement in cardiac function
as measured by improvement in ejection fraction as
measured by cardiac advanced imaging (cardiac MRI
(CMR) or CT).
Efficacy hypothesis
Intracoronary infusion of autologous bone marrow-
derived progenitor cells in patients who have undergone
successful PPCI for acute anterior myocardial infarction
will lead to an improvement in cardiac function greater
than that seen by placebo alone.
Study participants
This multicentre trial will recruit 100 patients who have
been admitted with a diagnosis of acute AMI treated suc-
cessfully with PPCI. Only patients with an AMI as
demonstrated by an anterior wall motion abnormality
on left ventriculography and with a culprit lesion in the
left anterior descending coronary artery will be eligible
for the study (see boxes 1 and 2). Patients with lesions
in other vessels that require treatment will be included
as long as they are treated during the index procedure
with the culprit vessel. Patients requiring staged proce-
dures will be excluded. Ptential patients will be
approached following the index primary PCI procedure.
Box 1 Inclusion criteria
Patients have to fulfil the following criteria:
▸ Patients presenting with acute anterior myocardial infarction
(ST elevation in at least 2 contiguous anterior leads ≥0.2 mV)
and treated with acute percutaneous coronary intervention
(PCI) with stent implantation within 24 h after symptom onset.
▸ Acute PCI/stent implantation has been successful (residual
stenosis visually <30% and TIMI flow ≥2).
▸ At the time of inclusion the patient no longer requires intraven-
ous catecholamines or mechanical hemodynamic support
(aortic balloon pump).
▸ Significant regional wall motion abnormality on left ventricular
angiogram in left anterior descending (LAD) territory at the
time of acute PCI.
▸ Age 18–80 years (primary angioplasty confers an adverse
prognosis in those over the age of 80 years).
▸ Written informed consent.
Figure 1 Flow diagram of study design. AMI, acute
myocardial infarction; BM, bone marrow; CMR, cardiac
magnetic resonance imaging; ECHO, echocardiogram; LV, left
ventricular.
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Centres participating in the trial are The London Chest
Hospital (London, UK), Royal Free Hospital (London,
UK), Heart Hospital (London, UK), Centre Hospitalier
Universitaire Vaudois (Lausanne, Switzerland) and
Rigshospitalet (Copenhagen, Denmark).
Randomisation and study blinding
Patients will be randomised to receive autologous BMCs
or matching placebo (in a 1:1 block randomisation allo-
cation) with the patient and treating clinicians blinded
to the assignment (double-blind). The randomisation
process will be performed by dedicated trial software
IHD CLINICAL. This is a web-based password secured
and encrypted data management system designed specif-
ically for clinical trials in this area.
Bone marrow aspiration and processing
Following consent, patients will undergo bone marrow
aspiration performed by a trained member of the
research team. The patient will be rolled onto their side
and local anaesthetic administered into the posterior
superior iliac spine. One hundred millilitres of bone
marrow will be aspirated into heparinised syringes and
the contents transferred to a specimen bag for transport
to the stem cell unit. The bone marrow is passed to the
cell culture laboratory of the hospital where the bone
marrow aspiration has been performed. The progenitor
cells will be isolated using Ficoll-Hypaque centrifugation.
The protocol for stem cell preparation has been previ-
ously set out by Schächinger et al.26 The autologous
BMCs or placebo will be placed in identical sterile syr-
inges and transferred back to the cardiac catheter
laboratories for the infusion procedure (Heparin will
not be included in the final solution for reinfusion).
Infusion procedure
Patients will return to the cardiac catheterisation labora-
tory once the cell processing is complete and the cells
are ready for collection (ideally within 6–8 h). A bolus
of body-weight-adjusted heparin will be given if the ACT
is <200. Progenitor cell infusion will be performed in
accordance with the protocol developed by Professor
Zeiher and collegues.20 A guide catheter will be used to
intubate the left coronary ostium and a 0.014-inch
guidewire will be introduced in the left anterior des-
cending artery. A 10 mm long ‘over-the-wire’ balloon
catheter will be positioned within the segment of the
previously implanted stent. The balloon diameter
should be ±0.5 mm the size of the implanted stent, to
achieve a complete vessel occlusion in the stented
segment during low-pressure balloon inflation. The
balloon catheter, used for the infusion of the cells, will
be occluded with low pressure (<2–4 bar). Prior to each
cell infusion, complete occlusion of the vessel will be
documented angiographically by injection of some con-
trast agent in the vessel. Ten millilitres of the cell suspen-
sion will be infused in three portions (each 3.3 mL)
during 3 min occlusion time for each portion. After
application of the first portion of the cell suspension,
the balloon will be deflated for 3 min, prior to the next
occlusion in order to avoid extensive ischaemia. Prior to
the first balloon occlusion and finally, after completion
of the cell infusion procedure, angiographically esti-
mated coronary blood flow and the integrity of the
treated will be documented and assessed by coronary
angiography. This method has been used in previous
trials with the aim to allow for adhesion and potential
transmigration of the infused cells through the
endothelium.18
Study endpoints
Blood samples are taken for local measurement of FBC,
U&E, LFTs, TFTS, creatine kinase, cardiac troponin T, C
reactive protein and brain natriuretic peptide. These are
again measured at the 6-month and 12-month visits.
Blood samples are also taken for HIV, hepatitis B and C,
HTLV and syphilis at time of randomisation, this is
required by the Stem Cell Laboratory for quality assur-
ance. Plasma samples will be obtained for storage in
cryovials at −80°C in UK centres only. These samples will
be used for further analysis and can be stored for up to
10 years in marked cryovials and in a locked −80°C
freezer with thaw protection system installed.
Box 2 Exclusion criteria
Patients are excluded if one of the following criteria is met:
▸ Regional wall motion abnormality not consistent with culprit
vessel;
▸ Need to revascularise additional vessels, outside the infarct
artery as a planned procedure (these vessels can be treated at
baseline);
▸ Arteriovenous malformations or aneurysms;
▸ Active infection, or fever or diarrhoea within the past 4 weeks;
▸ Chronic inflammatory disease;
▸ Known HIV infection or active hepatitis;
▸ Neoplastic disease without documented remission within the
past 5 years;
▸ Cerebrovascular insult within 3 months;
▸ Impaired renal function (creatinine >200 mmol) at the time of
cell therapy;
▸ Significant liver disease (gamma-glutamyltrasferase >2× upper
limit) or spontaneous International Normalised Ratio >1.5);
▸ Anemia (haemoglobin <8.5 mg/dL);
▸ Platelet count <100 000/µL;
▸ Hypersplenism;
▸ Known allergy or intolerance to clopidogrel, heparin or
abciximab;
▸ History of bleeding disorder;
▸ Gastrointestinal bleeding within 3 months;
▸ Major surgical procedure or trauma within 2 months;
▸ Uncontrolled hypertension;
▸ Pregnancy;
▸ Mental retardation leading to inability to obtain informed
consent;
▸ Previously performed stem/progenitor cell therapy;
▸ Participation in another clinical trial within the past 30 days.
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Primary endpoint
The primary efficacy endpoint for the study will be the
change in LVEF between baseline and 12 months
assessed by CMR. In patients who are clinically unable
to undergo CMR a cardiac CT scan will be performed as
an alternative.
Secondary endpoints include infarct size and myocar-
dial salvage at 3 months (CMR), change in global ejec-
tion fraction as measured by LV angiography after
6 months (quantitative analysis), and improvement in LV
function at 6 and 12 months as assessed by echocardiog-
raphy. Clinical endpoints include the acute safety and
tolerability of intracoronary stem cells following ST eleva-
tion myocardial infarction (haemodyamics and inpatient
major adverse cardiac events (MACE), heart failure
status (NYHA), heart failure admissions, quality of life
(UK sites only) and assessment of MACE endpoints at 6
and 12 months (death (independent of cause and
sudden death), myocardial infarction (Q-wave and
non-Q-wave), coronary revascularisation {(coronary
bypass or PCI)}). Further safety endpoints such as rates
of cardiac device, that is, implantable cardioverter defib-
rillator (ICD) insertion will be recorded at 1 year.
All data will be anonymised prior to analysis, which
will be performed by an independent member of the
department not associated with the trial. Scans will be
stored on a separate storage device to the reporting
system—either CD or encrypted hard drive.
Cardiac MRI
Each patient will undergo CMR on the day of hospital
discharge (Day 3), 3 months and 1 year following PPCI
using each site’s local CMR scanner. Each examination
will use cine-CMR for ventricular volumes and function,
and delayed enhancement (DE)-CMR for infarct size
assessment and evaluation of microvascular obstruction.
Myocardial oedema will be assessed at all time points
using three slice T2-weighted triple inversion turbo spin
echo short TI inversion recovery imaging. Myocardial
salvage will be calculated from the T2 imaging and
infarct size on the Day 3 scan. The inversion time will be
optimised to null normal myocardium. Images will be
analysed in a blinded fashion by two experienced opera-
tors. Scar and oedema volumes will be calculated by
manually drawing endocardial and epicardial contours
followed by semiautomated selection of normal remote
myocardium per slice. Infarct size will be calculated
using the full-width half maximum method as previously
described.27
CT imaging
Patients who are unable to undergo CMR will be imaged
using cardiac CT (approximately 5% of patients).
Analysis will use specialised cardiac CT circulation soft-
ware with intraventricular tracings of end systolic and
end diastolic timings.
Quantitative left ventriculography
The angiographic endpoint of the study is the change in
global LVEF at 6 months relative to baseline measured
by quantitative left ventriculography. LV angiography is
used as a secondary endpoint for the purpose of com-
parison to early trials such as REPAIR-AMI,20 that also
used LV angiographyas an endpoint. Left ventricular
angiography is performed in the 30° RAO position and
recorded at a minimum of 15–30 frames per second.
Contrast is injected over 10 s. At least two well-opacified
sinus beats that are not postpremature beats must be
obtained. A simultaneously recorded ECG must be sup-
plied as well as the aortic and LV pressures before and
after contrast injection. LVEF and volumes are calculated
with the centreline method.
Echocardiography
Echocardiography will be used to assess LV systolic func-
tion using wall motion scoring and calculation of ejec-
tion fraction using Simpson’s rule. Echocardiography
will be performed using imaging protocols that will be
standardised to ensure conformity. Assessment of LV
function will be performed on the day of PPCI prior to
stem cell infusion, 3 days after the PPCI (prior to dis-
charge), at 6 months and also at 1 year to track the
changes in cardiac function that occur over time as part
of this study.
Adjudication of potential endpoints
All measurements will be assessed and adjudicated by a
blinded expert. In the event of poor recordings, the
expert decides whether the measurement at hand is of
sufficient quality to be taken into the endpoint evalu-
ation. Measurements of insufficient quality are dealt
with in the analysis in the same manner as missing mea-
surements. Potential MACE events will be assessed by a
blinded Safety Committee. All core laboratory readings
and adjudications will be completed and entered into
the computer database before the study is unblinded.
Statistical analysis
To calculate the target sample size for the trial, an abso-
lute increase in ejection fraction of 6% compared to
baseline as measured by CMR will be considered signifi-
cant and consistent with previous studies that used
advanced imaging to measure endpoints.19 The pub-
lished SD for these observations is approximately 8%
and in keeping with what has been observed by Janssens
et al.21 For a statistical power of 90% and a probability of
a type I error of 0.05 using a two-sided t test, with an esti-
mated 25% dropout at 1 year we will recruit a total of
100 patients in this study. Previous trials have shown a
2% improvement in patients who underwent PPCI
alone.28 Therefore, using this information we will
perform a post hoc analysis to compare the two groups,
which will have 80% power to detect a 4% difference.
The analysis of the data will be based on the
intention-to-treat principle. Baseline demographic and
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clinical variables are summarised for each randomised
arm of the study. Continuous variables will be presented
as mean (SD) or median (IQR). Categorical data are
presented by frequencies and percentages.
The statistical comparisons within the treatment arms
with respect to the primary endpoint will be performed
using the independent-samples t test as the principal ana-
lytic tool. Further statistical comparison between treat-
ment arms with respect to the primary endpoint will be
performed using the analysis of covariance including
LVEF values at 12 months as dependent variables and the
associated baseline values and the factor treatment as
independent variables. Estimates of the treatment effect
are presented together with 95% CI. Comparisons will be
between the stem cell-treated and placebo control-treated
group for the primary and secondary outcomes.
Estimates of the treatment effects will be presented
together with 95% CIs. All p values will be two-sided.29
For clinical outcomes such as the incidence of MACE
(predefined clinical scenarios; death, myocardial infarc-
tion, re-admission for heart failure or revascularisation),
Kaplan-Meier curves displaying the pattern of events
during the 6-month and 12-month follow-up period are
drawn. Statistical significance and 95% CIs are calcu-
lated using Cox’s proportional hazards model.
Adverse events reporting
An independent Data and Safety and Monitoring Board
(DSMB) will be formed to monitor patient safety as the
study progresses. The DSMB has been selected by and
communicates directly to the study’s Executive
Committee. The DSMB will meet prior to initiation of
the clinical study to determine whether stopping rules
are needed or appropriate. If a serious concern with
the safety of the patients in the trial would arise, the
DSMB may recommend early termination of the study.
The DSMB will review safety issues throughout the
trial which will include unexpected serious adverse
events, mortality, complications of bone marrow aspir-
ation, complications of the intracoronary infusion, com-
plications of (diagnostic) study procedures and serious
or life-threatening arrhythmia’s. Every 3 months, all
safety events are reported to the DSMB statistician, who
will prepare tabulations by treatment groups. Fatalities
are reported on a case-by-case basis.
Ethical considerations
Important ethical issues to consider with this type of
trial are the need to obtain informed consent in the
acute setting, the possible risk of BMCs use, the require-
ment for further interventional angiography and infu-
sion shortly after the index procedure.
There are challenges in obtaining informed consent
from an acutely unwell patient with AMI, as both the
patient’s physical condition and treatment with pain
relief have the potential to make this difficult. A number
of steps will be taken to deal with this. First is to ensure
that patients are in a stable clinical condition when they
come back for repeat procedures, therefore we have
excluded patients who are unconscious, critically
unstable (cardiogenic shock) and deemed unable to
consent (ie, unable to understand in local language).
Second, all patients will be provided with a patient infor-
mation sheet prior to consent and the study will be dis-
cussed again with the patient after the procedure when
they are on the ward. Lastly, if the patient has been
given pain relief treatment or sedation during the initial
PPCI that could alter their decision-making we shall
ensure that the patient has enough time to recover prior
to consent.
BMCs are the patients’ own cells, therefore there is no
risk of an allergic reaction. The repeat angiography and
the infusion of BMCs or placebo into the coronary
artery could lead to possible complications but this will
be reduced by:
A. Using a low pressure inflation of the coronary
balloon that is 0.5 mm smaller than the stented
segment to reduce any dissection.
B. The infusion time will be divided into 3 min timed
slots with 3 min to reduce further ischaemia.
Dissemination
The study will be performed in agreement to the
Declaration of Helsinki. Data collection will be completed
by mid-2014. Primary and secondary analysis will start
immediately after data monitoring is completed.
Publications will be prepared for submission in late 2014.
The results of the trial will be published according to the
CONSORT statement. Dissemination of results will focus
on publications in peer-reviewed journals, presentations at
both national and international cardiology meetings and
National Health Service (NHS) groups. In accordance
with recommendations, REGENERATE-AMI has been
registered with a public registry ClinicalTrials.gov.
Summary
REGENERATE-AMI will be the first RCT of autologous
bone marrow-derived cells delivered to patients less than
24 h after presentation with acute AMI. The results of
the study will demonstrate whether such early delivery is
achievable and safe. The efficacy results of this trial will
complete a time course for cell administration that has
been complied as a result of previous studies and will
therefore provide valuable information for the planning
of future phase III clinical trials using autologous cell
therapy in AMI.
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